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Abstract: Bacterial endotoxin lipopolysaccharide (LPS)-induced sepsis is a critical  
medical condition, characterized by a severe systemic inflammation and rapid loss of muscle 
mass. Preventive and therapeutic strategies for this complex disease are still lacking. Here, 
we evaluated the effect of omega-3 (n-3) polyunsaturated fatty acid (PUFA) intervention on 
LPS-challenged mice with respect to inflammation, body weight and the expression of  
Toll-like receptor 4 (TLR4) pathway components. LPS administration induced a dramatic 
loss of body weight within two days. Treatment with n-3 PUFA not only stopped loss of 
body weight but also gradually reversed it back to baseline levels within one week. Accordingly, 
the animals treated with n-3 PUFA exhibited markedly lower levels of inflammatory 
cytokines or markers in plasma and tissues, as well as down-regulation of TLR4 pathway 
components compared to animals without n-3 PUFA treatment or those treated with omega-6 
PUFA. Our data demonstrate that n-3 PUFA intervention can suppress LPS-induced 
inflammation and weight loss via, at least in part, down-regulation of pro-inflammatory 
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targets of the TLR4 signaling pathway, and highlight the therapeutic potential of n-3 PUFA 
in the management of sepsis. 
Keywords: n-3 polyunsaturated fatty acids; lipopolysaccharide; inflammation; muscle 
atrophy; TLR4; sepsis 
 
1. Introduction 
Sepsis is a potentially life-threatening complication of an infection, characterized by a systemic 
inflammatory response syndrome and rapid loss of muscle mass and myofibrillar protein content, or 
muscle atrophy [1,2]. Lipopolysaccharide (LPS), an endotoxin located on the outer cell membrane of 
Gram-negative bacteria, is a major factor triggering septic shock and inflammatory response [3].  
The global incidence of sepsis and septic shock has increased over the past two decades and is predicted 
to continue to rise over the next 20 years [1]. Identification of safe and effective means for the management 
of sepsis is warranted. Nutritional modulation aimed at suppressing the release of pro-inflammatory 
cytokines and preventing weight loss may be of potential benefit in attenuating muscle atrophy and 
inflammation during sepsis. 
Accumulating evidence indicates that omega-3 (n-3) polyunsaturated fatty acids (PUFA) such as 
eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) play beneficial roles 
in the management of inflammatory diseases [4–6]. Omega-3 PUFA have also been shown to improve 
muscle protein synthesis [7,8], and alleviate muscle atrophy in cancer [9] and sepsis [10]. Collectively, 
these data suggest that n-3 PUFA represent potentially novel therapeutic agents for critically ill and 
severely injured patients who commonly present with inflammation and weight loss problems. The 
majority of studies in this area, however, have focused on the preventive effects of fish oil (FO) through 
dietary supplementation [11,12]. Whether FO intervention is effective in suppressing LPS-induced 
inflammation and weight loss requires further investigation. Moreover, although the beneficial role of 
n-3 PUFA is thought to be associated with their inhibitory effects on overproduction of pro-inflammatory 
cytokines [4–6], the specific signaling pathways are unclear. 
Toll-like receptors (TLRs) play critical roles in the induction of inflammatory and immune  
responses against conserved microbial structures, referred to as pathogen-associated molecular patterns 
(PAMPs) [13]. One such PAMP is LPS. TLR4 is a subclass of the TLR family involved in the activation 
of the innate immune and inflammatory response in mammals upon the binding of LPS [14,15]. The 
intestine is rich in TLR4 receptors and is often the first organ to respond to increased LPS generated by 
intestinal bacteria. The interaction of TLR4 subclass members with LPS and other PAMPs engages 
intracellular signaling pathways that culminate in the activation of nuclear factor κB (NFκB) and the 
induction of inflammatory genes encoding tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and 
IL-6 [16]. Moreover, inhibition by unsaturated fatty acids of LPS-induced NFκB activation has been 
attributed to suppression of TLR4-derived signaling pathways [17]. In this context, this study was designed 
to test the hypothesis that intervention with n-3 PUFA-containing FO protects against LPS-induced 
weight loss and inflammatory cytokine production by suppressing the TLR4 signaling pathway. 
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2. Results 
2.1. Effect of FO Intervention on LPS-Induced Weight Loss 
Following the challenge with LPS (3.5 mg/kg intraperitoneal injection), body weight (BW) and food 
intake were monitored daily. During the study period, total food intake did not differ significantly among 
the four groups (Table 1). As anticipated, compared with the control group without LPS challenge, body 
weight on Day 2 after LPS administration was significantly reduced in all LPS-treated animals (LPS, 
LPS + CO, and LPS + FO) (Figure 1A). Interestingly, supplementation of the LPS-challenged mice with 
fish oil containing 63% EPA and DHA (by gavage of 100 µL·FO/mouse/day) stopped BW drop and 
even raised it gradually, resulting in a significant difference in BW on Day 8 between the animals treated 
with FO (LPS + FO) and those without supplementation (LPS) or with corn oil (CO, containing 62%  
n-6 PUFA) supplementation (LPS + CO) (Figure 1A). Furthermore, analysis of the net BW change over 
the course of the study (Figure 1B) indicated that FO intervention opposed LPS-induced weight loss in 
the mice. 
Table 1. Weight of food intake per day (g) of mice during the study (n = 6). 
Group 1 day 2 days 3 days 4 days 5 days 6 days 7 days 8 days 
Control 3.38 ± 0.08 3.20 ± 0.09 3.29 ± 0.08 3.19 ± 0.09 3.24 ± 0.16 3.09 ± 0.08 2.97 ± 0.08 3.15 ± 0.11 
LPS 3.37 ± 0.14 3.33 ± 0.11 3.21 ± 0.13 3.19 ± 0.08 3.00 ± 0.14 2.98 ± 0.06 2.96 ± 0.10 3.11 ± 0.13 
LPS + CO 3.42 ± 0.09 3.23 ± 0.12 3.24 ± 0.09 3.06 ± 0.09 3.19 ± 0.14 3.02 ± 0.10 2.94 ± 0.12 3.08 ± 0.12 
LPS + FO 3.30 ± 0.10 3.17 ± 0.09 3.23 ± 0.10 3.11 ± 0.11 3.13 ± 0.12 2.98 ± 0.12 2.97 ± 0.08 3.14 ± 0.09 
F 0.7475 1.447 0.3475 1.228 3.2200 0.8075 0.0600 0.3000 
P 0.5536 0.2997 0.7922 0.3613 0.0826 0.5243 0.9794 0.8247 
CO, corn oil; FO, fish oil. LPS + CO and LPS + FO groups received additional calories per day by gavage (~6% of total energy intake). 
 
Figure 1. Effect of fish oil (FO) intervention on body weight in LPS-challenged mice. 
Animals were challenged with LPS on Day 1, with FO and CO intervention on Day 2. (A) Body 
weight measurements taken over the study duration; (B) Net body weight change. Values 
are means ± SE (n = 6). * p < 0.05 compared to the control group, # p < 0.05 compared to 
the LPS group, & p < 0.05 compared to the LPS plus corn oil (LPS + CO) group. 
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2.2. Effect of FO Intervention on LPS-Induced Inflammation 
We next examined the effect of FO on LPS-induced changes in the levels of inflammation-related 
cytokines. As LPS was administered by intraperitoneal injection, and may readily interact with the 
abundant TLR4 receptors in the intestine, we measured changes in inflammatory status in the plasma 
and intestine. LPS challenge induced a dramatic increase in the levels of IL-1β, IL-6, and TNF-α in both 
plasma and small intestine (Figure 2), as measured by multiplex immunoassay. FO intervention markedly 
reduced the small intestine and plasma levels of the inflammatory cytokines, whereas CO supplementation 
failed to decrease the cytokine levels significantly, as the cytokine levels in the LPS + FO group, but not 
in the LPS + CO group, were significantly lower than those of the LPS group (Figure 2). In addition, 
examination of mRNA expression levels of TNF-α, IL-1β, and IL-6 in the small intestine tissue showed 
a similar suppressing effect by FO intervention (Figure 3). Furthermore, we measured plasma ALT and 
AST activities as markers of liver inflammation. As shown in Figure 4, LPS challenge resulted in 
increased plasma levels of both ALT and AST, which were significantly reduced by FO intervention, 
suggesting that omega-3 PUFA protect against LPS-induced liver inflammation and damage. 
 
Figure 2. Effect of fish oil (FO) intervention on cytokine levels in lipopolysaccharide  
(LPS)-challenged mice. Small intestine tissue levels of (A) IL-1β; (B) IL-6; (C) TNF-α; and 
(D) MCP-1. Plasma levels of (E) IL-1β; (F) IL-6; (G) TNF-α; and (H) MCP-1. Values are 
means ± SE (n = 6). * p < 0.05 compared to the control group, # p < 0.05 compared to the 
LPS group, & p < 0.05 compared to the LPS + CO group. 
2.3. Effect of FO Intervention on the Expression of TLR4 Pathway Components 
We proceeded to evaluate the effects of FO intervention on LPS-induced changes in the levels of 
components of the TLR4 signaling pathway. LPS challenge remarkably upregulated small intestine 
expression of TLR4 and MyD88, as shown by increased levels of both mRNA and protein of these 
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factors (Figure 5). Interestingly, FO intervention, but not CO intervention, was able to significantly 
suppress the LPS-induced upregulation of the genes (Figure 5). Furthermore, we determined the mRNA 
levels of downstream components of the TLR4 pathway, such as NFκB, COX2, and iNOS, in the small 
intestine. As shown in Figure 6, the increased expression of NFκB and COX2 induced by LPS challenge 
could be significantly suppressed by FO intervention, but not CO intervention. Similar results on the 
differential effects of FO and CO interventions on the expression of the pathway components were found 
in skeletal muscle (Figure 7). These data indicate that FO intervention can down-regulate pro-inflammatory 
targets of the TLR4 signaling pathway. 
 
Figure 3. Effect of FO intervention on small intestine mRNA levels of cytokine genes in 
LPS-challenged mice. Values are means ± SE (n = 6). * p < 0.05 compared to the control 
group, # p < 0.05 compared to the LPS group, & p < 0.05 compared to the LPS + CO group. 
 
Figure 4. Effect of FO intervention on plasma ALT (A) and AST (B) activities in  
LPS-challenged mice. Values are means ± SE (n = 6). * p < 0.05 compared to the control 
group, # p < 0.05 compared to the LPS group, & p < 0.05 compared to the LPS + CO group. 
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Figure 5. Effect of FO intervention on mRNA (A) and protein (B-C) expression of TLR4 
and myD88 in small intestine of LPS-challenged mice. Values are means ± SE (n = 6 for 
mRNA expression, n = 3 for protein expression). (B) Western blot images; (C) Gray-scale 
analysis of Western blot images. * p < 0.05 compared to the control group, # p < 0.05 
compared to the LPS group, & p < 0.05 compared to the LPS + CO group. 
 
Figure 6. Effect of FO intervention on small intestine mRNA levels of TLR4 signaling 
pathway factors in LPS-challenged mice. Values are means ± SE (n = 6). * p < 0.05 
compared to the control group, # p < 0.05 compared to the LPS group, & p < 0.05 compared 
to the LPS + CO group. 
 
Figure 7. Effect of FO intervention on muscle mRNA levels of TLR4 signaling pathway 
factors in LPS-challenged mice. mRNA relative expression of (A) TLR4 and MyD88;  
(B) NFκB and TNF-α; (C) COX-2 and iNOS. Values are means ± SE (n = 6). * p < 0.05 
compared to the control group, # p < 0.05 compared to the LPS group, & p < 0.05 compared 
to the LPS + CO group.  
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3. Discussion 
Septic shock encompasses a variety of systemic and cellular processes that collectively lead to 
overproduction of inflammatory mediators and culminate in weight loss, organ failure, and death. The 
Gram-negative bacterial endotoxin LPS is a potent activator of the immune system, inducing the 
production of inflammatory mediators, such as TNF-α, IL-1β and IL-6, which have been implicated in 
the early phase of shock [1,3]. In this study, we used i.p. injection of LPS to induce septic conditions 
and to test the interventional effects of n-3 PUFA. Our data demonstrated that n-3 PUFA FO can 
significantly reduce weight loss and inflammatory status, the two major manifestations of sepsis. 
Omega-3 fatty acids, such as EPA and DHA mainly found in FO, have been shown to decrease the 
production of inflammatory cytokines and exert beneficial effects on inflammation-related diseases in 
animal models and clinical trials [4–6]. Consistent with these observations, we found that FO intervention 
resulted in decreased tissue levels of TNF-α, IL-1β, and IL-6 and decreased plasma ALT and AST 
activities, indicating reduced systemic and hepatic inflammation. In this study, we used corn oil (containing 
60% n-6 PUFA) as an isoenergetic control for the FO group, and found that CO supplementation did not 
result in similar benefits, suggesting a differential effect of n-6 and n-3 PUFA on septic conditions. It is 
notable that the CO intervention group did exhibit some beneficial effects against the decline in body 
weight, but not inflammatory status. This may be due to the additional energy intake from fat provided 
by CO intervention, compared to the LPS group. 
TLR4 is involved in the recognition of LPS in the outer membrane of Gram-negative bacteria and 
helps to trigger the subsequent inflammatory response [18,19]. When bound by LPS, the TLR4/CD14/LBP 
receptor complex engages MyD88 to trigger a downstream signaling cascade that results in activation 
of NFκB and the inductions of genes encoding pro-inflammatory cytokines and COX2 [18]. In this 
context, we designed our study to examine whether FO intervention affects factors involved in the  
LPS-induced TLR4 signaling pathway. Given that the main physiological effect of LPS challenge was 
weight loss, secondary to intestine and muscle atrophy, we focused on evaluating the expression levels 
of TLR4 signaling pathway components and transcriptional targets in intestine and skeletal muscle.  
We found that FO intervention suppressed the LPS-induced upregulation of TLR4, MyD88, NFκB, 
TNF-α, IL-1β, and COX2 in both tissues. These findings suggest that the beneficial effects of FO 
intervention on LPS-induced weight loss and inflammation may be associated with the suppression of 
TLR4 signaling. A limitation of this study is the lack of data on body composition among the groups, 
which would provide further insight into the effects of FO intervention. 
To date, few in vivo studies have examined the role of n-3 PUFA in the modulation of TLR  
signaling [20–22]. One such study by Liu et al. [20] suggested that fish oil may suppress muscle  
pro-inflammatory cytokine production in weanling piglets via regulation of TLR and NOD signaling 
pathways. Nevertheless, several in vitro studies have reported that n-3 EPA and DHA inhibit the 
activation of TLR4 and the expression of its target genes [23]. Moreover, n-3 PUFA have been shown 
to inhibit LPS or lauric acid-induced activation of TLR4 through inhibition of receptor dimerization  
and recruitment into lipid rafts in a reactive oxygen species-dependent manner [24]. Our findings that 
FO intervention in mice suppresses LPS-induced expression of inflammatory cytokines and factors in 
the TLR4 signaling pathway support the notion that modulation of TLR4 pathway signaling is a key 
anti-inflammatory mechanism of n-3 PUFA. 
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4. Materials and Methods 
4.1. Animals and Treatment 
Nine-week old male C57BL/6 mice (n = 24) were purchased from Charles River Laboratories (Boston, 
MA, USA). All mice were housed in metal barred cages (3 mice/cage), had 12-h light and dark cycles, 
and were fed a regular chow diet. After arrival, mice went through a 7-day acclimatization period, after 
which six mice were designated as the control group and injected with 0.1 mL PBS, while the remaining 
18 mice were challenged with 3.5 mg/kg intraperitoneal LPS (Escherichia coli 026:B6; Sigma-Aldrich, 
Co., St. Louis, MO, USA). On day 2, the 18 LPS-challenged mice were assigned to one of the following 
treatment groups (administered by gavage, 0.1 mL/animal/day): LPS group: PBS; LPS + fish oil (FO) 
group: FO (EPA 43%, DHA 20%, other n-3: 2%); and LPS + corn oil (CO): CO (62% n-6 LA). The FO 
and CO content accounted for ~6% of total energy intake. Food intake and body weight were measured 
every day and the study was terminated when the average body weight in the LPS group reached 20% 
of its value at baseline. At study termination, mice were sacrificed by intraperitoneal injection with ketamine 
(100 mg/kg) and xylazine (10 mg/kg), blood samples were taken and plasma was generated by 
centrifugation prior to storage at −80 °C for further analysis. Small intestine and gastrocnemius muscle 
tissue were dissected and immersed in liquid N2 before storage at −80 °C. 
All animal experimental protocols were approved by the Institutional Animal Care and Animal Ethics 
Committee of Massachusetts General Hospital (Boston, MA, USA). 
4.2. Systemic Inflammation Measurement 
Concentrations of TNF-α, IL-1β, IL-6 and monocyte chemoattractant protein 1 (MCP-1), were 
determined in 15 μL of plasma and small intestine PBS homogenates using a multiplex immunoassay 
kit (Bio-Plex Pro™ Mouse Cytokine Assay, Bio-Rad, Waltham, MA, USA) and measured using 
Luminex® technology (Bioplex®, Bio-Rad, Waltham, MA, USA). The extent of liver inflammation was 
determined by measurement of plasma alanine transaminase (ALT) and aspartate transaminase (AST) 
activity using Alanine Transaminase and Aspartate Transaminase Enzymatic Assay Kits (BIOO 
Scientific Corp., Austin, TX, USA) following the manufacturer’s protocols. 
4.3. Gene Expression Measurement 
Total RNA was isolated from small intestine and gastrocnemius muscle using Trizol reagent 
(Invitrogen, Carlsbad, CA, USA). cDNAs were synthesized from 1 μg of RNA using iScrip™ Reverse 
Transcription Supermix (Bio-Rad, Waltham, MA, USA) for RT-PCR. After cDNA synthesis, Q-PCR 
was performed in 20 μL of iTaqTM Universal SYBR® Green Supermix (Bio-Rad, Waltham, MA, USA), 
using a fluorometric thermal cycler (Stratagene Mx3005P PCR Detection System, Agilent Technologies, 
Santa Clara, CA, USA). All primers were synthesized by Invitrogen (Carlsbad, CA, USA). All samples 
were processed in triplicate and normalized to β-actin. The expression levels were calculated using the 
ΔΔCt method after correcting for differences in PCR efficiencies, and values were expressed relative to 
those of the control group. 
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4.4. Western Blotting Analysis 
Small intestine total protein extracts were prepared using RIPA buffer, and protein concentrations 
were measured using a BCA kit (Pierce, Rockford, IL, USA). Proteins (50 μg) were separated by 
electrophoresis on a 4%–12% SDS–PAGE gel and transferred to PVDF membranes (Invitrogen, 
Carlsbad, CA, USA). The primary antibodies were mouse anti-TLR4 and MyD88 (1:1000; GeneTex). 
The secondary antibodies were horseradish peroxidase (HRP)-conjugated ECL rabbit anti-mouse IgG 
(1:4000; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Chemiluminescent detection was performed 
using the ECL method (Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
4.5. Statistical Analysis 
All data are presented as the mean ± standard error of the mean. Statistical analysis was performed 
with ANOVA and Tukey’s test by using SPSS software version 17.0. A p < 0.05 was considered to be 
statistically significant. 
5. Conclusions 
In summary, our study demonstrates that FO intervention suppresses LPS-induced inflammation  
and weight loss, associated with down-regulation of pro-inflammatory targets of the TLR4 signaling 
pathway, and suggests that n-3 PUFA may serve as potential therapeutics for the management of 
inflammatory diseases. 
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